Skip to content

Practice- and provider-level inequities in next-generation sequencing testing by race/ethnicity for patients with advanced non-small cell lung cancer treated in the community setting

Published

May 2023

Citation

Vidal G, Jain N, Fisher A, Sheinson D, Lofgren K, Ma E, Yu E, Comment L, Miksad R, Daniel D. Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting. Poster presented at: 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Accessed May 25, 2023. https://meetings.asco.org/abstracts-presentations/219916 

Summary

Disparities in the provision of next-generation sequencing (NGS) testing for advanced non-small cell lung cancer patients have been widely reported. However, it is unknown if NGS testing inequity is driven by differential care within the same practice or provider; and/or by the disproportionate share of historically marginalized patients receiving care at practices and/or providers with lower NGS testing rates overall. To comprehensively assess the total inequity in NGS testing for this patient population, researchers examined inequities within and across practice and providers. 

Why this matters

The findings from this study can help researchers and policy-makers identify areas where policy interventions can be implemented to promote greater equity in access to NGS testing.  

Read the research

Share